Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
← catalyst calendarNCT06152237 · readout in 806 d
Sponsored by Taysha Gene Therapies, Inc. (industry) · TSHA — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
6actual
Sites
5
Countries
Canada, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-12 | actual | When the study began enrolling |
| Primary completion | 2028-11-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-11-02 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rett Syndrome
Intervention
- Genetic: TSHA-102
Primary outcome
what the primary-completion date above is the date OFPrimary Safety
measured Baseline through week 52
Permalink · TSHA's whole pipeline · Catalyst calendar · Every registered study · What changed